TLPH Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 1.02
- PEG ratio
- —
- P/B
- 2.73
- P/S (TTM)
- 50347.85
- EV/EBITDA
- 0.11
Profitability & growth
- ROE (TTM)
- -118.4%
- Operating margin
- -1451600.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 0.79
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Talphera Inc.
Company profileTalphera Inc. is an innovative biotechnology firm focused on developing cutting-edge peptide-based therapies aimed at rare diseases and substantial unmet medical needs. The company’s robust pipeline, particularly in the realm of novel cancer treatments, underscores its potential for significant growth in the biopharmaceutical sector. With a strong commitment to research and a mission to deliver transformative health solutions, Talphera presents an attractive investment opportunity for institutional investors interested in the evolving landscape of biotechnology.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1850 GATEWAY DRIVE, SAN MATEO, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer